Maura Massimino1, Rosalba Miceli1, Felice Giangaspero1, Luna Boschetti1, Piergiorgio Modena1, Manila Antonelli1, Paolo Ferroli1, Daniele Bertin1, Emilia Pecori1, Laura Valentini1, Veronica Biassoni1, Maria Luisa Garrè1, Elisabetta Schiavello1, Iacopo Sardi1, Armando Cama1, Elisabetta Viscardi1, Giovanni Scarzello1, Silvia Scoccianti1, Maurizio Mascarin1, Lucia Quaglietta1, Giuseppe Cinalli1, Barbara Diletto1, Lorenzo Genitori1, Paola Peretta1, Anna Mussano1, Annamaria Buccoliero1, Giuseppina Calareso1, Salvina Barra1, Angela Mastronuzzi1, Carlo Giussani1, Carlo Efisio Marras1, Rita Balter1, Patrizia Bertolini1, Ermanno Giombelli1, Milena La Spina1, Francesca R Buttarelli1, Bianca Pollo1, Lorenza Gandola1. 1. Department of Pediatrics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (M.M., L.B., V.B., E.S.); Department of Medical Statistics, Biometry, and Bioinformatics, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (R.M.); Pediatric Radiotherapy, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (L.G., E.P., B.D.); Department of Radiology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy (G.C.); Department of Radiological, Oncological, and Anatomo-Pathological Sciences, Sapienza University, Rome, Italy (F.G., M.A.); Department of Neurology and Psychiatry, Sapienza University, Rome, Italy (F.R.B.); IRCCS Neuromed, Pozzilli, Italy (F.G.); Laboratory of Genetics, Pathology Unit, S. Anna General Hospital, Como, Italy (P.M.); Neurosurgery Department, IRCCS Istituto Neurologico Carlo Besta, Milan, Italy (P.F., L.V.); Pathology Unit, IRCCS Istituto Neurologico Carlo Besta, Milan, Italy (B.P.); Department of Pediatric Onco-Hematology, Regina Margherita Children's Hospital, Torino, Italy (D.B.); Department of Neurosurgery, Regina Margherita Children's Hospital, Torino, Italy (P.P.); Radiotherapy Unit, Regina Margherita Children's Hospital, Torino, Italy (A.M.); Istituto Giannina Gaslini, Genova, Italy (M.L.G., A.C.); Department of Neuro-oncology, Ospedale Pediatrico Meyer, Firenze, Italy (I.S.); Neurosurgery Unit, Ospedale Pediatrico Meyer, Firenze, Italy (L.G.); Pediatric Oncology Unit, Padova University, Padova, Italy (E.V.); Radiotherapy Department, IOV-IRCCS, Padova, Italy (G.S.); Department of Radiation Oncology, Careggy Hospital, Firenze, Italy (S.S.); Pathology Unit, Careggy Hospital, Firenze, Italy (A.B.); Department of Pediatric Radiotherapy, CRO, Aviano, Italy (M.M.); Department of Pediatric Oncology, Ospedale Santobono-Pausillipon, Napoli, Italy (L.Q.); Neurosurgery Unit, Ospedale Santobono-Pausillipon, Napoli, Italy (G.C.); Department of Radiation Oncology, IRCCS San Martino IST, National Cancer Research Institute, Ge
Abstract
BACKGROUND: This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). METHODS: WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. RESULTS: From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. CONCLUSIONS: In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
BACKGROUND: This prospective study stratified patients by surgical resection (complete = NED vs incomplete = ED) and centrally reviewed histology (World Health Organization [WHO] grade II vs III). METHODS: WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4 courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1-4 VEC courses, second-look surgery, and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1-3 years with grade II tumors could receive 6 VEC courses alone. RESULTS: From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y; males, 100). Follow-up was a median of 67 months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multivariable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable. CONCLUSIONS: In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters emerging in this series will be the object of future correlatives and reports.
Authors: J Grill; M C Le Deley; D Gambarelli; M A Raquin; D Couanet; A Pierre-Kahn; J L Habrand; F Doz; D Frappaz; J C Gentet; C Edan; P Chastagner; C Kalifa Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: Thomas E Merchant; Jesse J Jenkins; Peter C Burger; Robert A Sanford; Scot H Sherwood; Dana Jones-Wallace; Richard L Heideman; Stephen J Thompson; Kathleen J Helton; Larry E Kun Journal: Int J Radiat Oncol Biol Phys Date: 2002-05-01 Impact factor: 7.038
Authors: Hendrik Witt; Stephen C Mack; Marina Ryzhova; Sebastian Bender; Martin Sill; Ruth Isserlin; Axel Benner; Thomas Hielscher; Till Milde; Marc Remke; David T W Jones; Paul A Northcott; Livia Garzia; Kelsey C Bertrand; Andrea Wittmann; Yuan Yao; Stephen S Roberts; Luca Massimi; Tim Van Meter; William A Weiss; Nalin Gupta; Wiesia Grajkowska; Boleslaw Lach; Yoon-Jae Cho; Andreas von Deimling; Andreas E Kulozik; Olaf Witt; Gary D Bader; Cynthia E Hawkins; Uri Tabori; Abhijit Guha; James T Rutka; Peter Lichter; Andrey Korshunov; Michael D Taylor; Stefan M Pfister Journal: Cancer Cell Date: 2011-08-16 Impact factor: 31.743
Authors: Heather J McCrea; Evan D Bander; Rachael A Venn; Anne S Reiner; J Bryan Iorgulescu; Luis A Puchi; Peter M Schaefer; Gustav Cederquist; Jeffrey P Greenfield Journal: Neurosurgery Date: 2015-09 Impact factor: 4.654
Authors: Arthur K Liu; Nicholas K Foreman; Laurie E Gaspar; Elizabeth Trinidad; Michael H Handler Journal: Pediatr Blood Cancer Date: 2009-07 Impact factor: 3.167
Authors: Richard G Grundy; Sophie A Wilne; Claire L Weston; Kath Robinson; Linda S Lashford; James Ironside; Tim Cox; W Kling Chong; Richard H A Campbell; Cliff C Bailey; Rao Gattamaneni; Sue Picton; Nicky Thorpe; Conor Mallucci; Martin W English; Jonathan A G Punt; David A Walker; David W Ellison; David Machin Journal: Lancet Oncol Date: 2007-08 Impact factor: 41.316
Authors: Santhosh A Upadhyaya; Giles W Robinson; Arzu Onar-Thomas; Brent A Orr; Catherine A Billups; Daniel C Bowers; Anne E Bendel; Tim Hassall; John R Crawford; Sonia Partap; Paul G Fisher; Ruth G Tatevossian; Tiffany Seah; Ibrahim A Qaddoumi; Anna Vinitsky; Gregory T Armstrong; Noah D Sabin; Christopher L Tinkle; Paul Klimo; Danny J Indelicato; Frederick A Boop; Thomas E Merchant; David W Ellison; Amar Gajjar Journal: Neuro Oncol Date: 2019-10-09 Impact factor: 12.300
Authors: Brian De; Yasmin Khakoo; Mark M Souweidane; Ira J Dunkel; Suchit H Patel; Stephen W Gilheeney; Kevin C De Braganca; Matthias A Karajannis; Suzanne L Wolden Journal: J Neurooncol Date: 2018-03-06 Impact factor: 4.130
Authors: Martin Benesch; Martin Mynarek; Hendrik Witt; Monika Warmuth-Metz; Torsten Pietsch; Brigitte Bison; Stefan M Pfister; Kristian W Pajtler; Marcel Kool; Ulrich Schüller; Klaus Pietschmann; Björn-Ole Juhnke; Stephan Tippelt; Gudrun Fleischhack; Irene Schmid; Christof M Kramm; Peter Vorwerk; Andreas Beilken; Carl Friedrich Classen; Pablo Hernáiz Driever; Gabriele Kropshofer; Thomas Imschweiler; Andreas Lemmer; Rolf-Dieter Kortmann; Stefan Rutkowski; Katja von Hoff Journal: Oncologist Date: 2019-03-08
Authors: Thomas E Merchant; Anne E Bendel; Noah D Sabin; Peter C Burger; Dennis W Shaw; Eric Chang; Shengjie Wu; Tianni Zhou; David D Eisenstat; Nicholas K Foreman; Christine E Fuller; Edwina Templeton Anderson; Juliette Hukin; Ching C Lau; Ian F Pollack; Fred H Laningham; Robert H Lustig; Floyd D Armstrong; Michael H Handler; Chris Williams-Hughes; Sandra Kessel; Mehmet Kocak; David W Ellison; Vijay Ramaswamy Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Eveline Teresa Hidalgo; Matija Snuderl; Cordelia Orillac; Svetlana Kvint; Jonathan Serrano; Peter Wu; Matthias A Karajannis; Sharon L Gardner Journal: Childs Nerv Syst Date: 2019-08-02 Impact factor: 1.475
Authors: Derek S Tsang; Louise Murray; Vijay Ramaswamy; Michal Zapotocky; Uri Tabori; Ute Bartels; Annie Huang; Peter B Dirks; Michael D Taylor; Cynthia Hawkins; Eric Bouffet; Normand Laperriere Journal: Neuro Oncol Date: 2019-03-18 Impact factor: 12.300